[Market Focus] G2GBio Surges Over 60% on First Day of KOSDAQ Listing

G2GBio is surging more than 60% in early trading on its first day listed on KOSDAQ.

As of 9:18 a.m. on August 14, 2025, G2GBio's share price stood at 96,300 won, up 66.03% from its IPO price of 58,000 won. Shares opened at 86,500 won and at one point during the session soared to 97,600 won.

Founded in 2017, G2GBio specializes in the development of long-acting (sustained-release) pharmaceuticals. The company possesses next-generation microsphere platform technology that meets the demand for extended half-life drug development. This technology offers versatility, allowing for the incorporation of various drugs including synthetic pharmaceuticals, peptide drugs, antibody drugs, and RNA therapeutics. G2GBio has also secured global-scale mass production capabilities.

In the public offering subscription for retail investors held on August 5 and 6, the competition ratio reached 470.1 to 1, with approximately 3.0675 trillion won in subscription deposits collected. Previously, in the institutional investor book-building conducted from July 25 to 31, a total of 2,446 institutions participated, resulting in a competition ratio of 810.6 to 1. The final IPO price was set at the upper end of the price band, 58,000 won.

The funds raised through the IPO will be used for the expansion of the first GMP plant, construction of a second GMP plant, and pipeline expansion.